> France's bioMérieux reported a 7% jump in full-year 2014 revenues, with its acquisition of BioFire Diagnostics contributing €78 million ($88.7 million). Article (reg. req.)
> AltheaDx set the terms for its previously announced IPO, planning to raise $60 million by offering 4.6 million shares at a price range of $12 to $14. The company will list on the NASDAQ under the symbol "IDGX." More
> bioMérieux and Astute Medical are teaming up to develop Astute's test for acute kidney injury. Story
> Danaher ($DHR) posted a 3% increase in revenue during the fourth quarter of 2014, with platform sales for its diagnostics business up in the mid-single digits. More
> Natera has selected DNAnexus' cloud-based platform to share, analyze and store results from its noninvasive prenatal diagnostic tests. Story
> Swiss diagnostic outfit ProteoMediX raked in 1 million Swiss francs ($1.1 million) in a Series B round to support development of its noninvasive tests for cancer. Release
> Agilent Technologies ($A) won approval from the China Food and Drug Administration for its SureScan Dx microarray scanner for in vitro diagnostic use. Story
> MetaStat struck a deal with Kaiser Foundation Hospitals to access tumor samples and clinical data from patients with or without systemic metastasis, supporting development of its epigenetic-based tests for early detection of breast cancer. More
And Finally… Myriad Genetics ($MYGN) launched a new social media campaign, dubbed #ProstateAnswers, to raise public awareness about genetic testing for men with prostate cancer. Release